文献速递细菌感染、耐药与抗菌药物医院感染防控

危重症患者β-内酰胺类抗生素治疗药物监测:系统综述与荟萃分析

Beta-Lactam Antibiotic Therapeutic Drug Monitoring in Critically Ill Patients: A Systematic Review and Meta-Analysis.
PubMed 文献 · Clin Infect Dis · 2022-01-01

该系统综述与荟萃分析纳入11项研究共1463例疑似或确诊脓毒症的危重症患者,评估TDM指导给药对临床结局的影响。TDM指导给药与临床治愈、微生物学治愈、治疗失败及目标 attainment 改善相关,但与死亡率和住院时长无关联。作者认为需要更大规模的前瞻性随机试验来更好地评估β-内酰胺类TDM在危重症患者中的效用。

要点

  • TDM指导给药与临床治愈改善相关(RR 1.17,95%CI 1.04-1.31)。
  • TDM指导给药与微生物学治愈改善相关(RR 1.14,95%CI 1.03-1.27)。
  • TDM指导给药与治疗失败降低相关(RR 0.79,95%CI 0.66-0.94),与目标 attainment 改善相关(RR 1.85,95%CI 1.08-3.16)。

核心结论

  • TDM指导给药改善了临床治愈、微生物学治愈和治疗反应。
  • 需要更大规模的前瞻性随机试验来更好地评估β-内酰胺类TDM在危重症患者中的效用。

研究设计与样本

  • 系统综述与荟萃分析,纳入11项研究,共1463例疑似或确诊脓毒症的危重症患者。

主要发现

  • TDM指导给药与临床治愈改善相关(RR 1.17,95%CI 1.04-1.31)。
  • TDM指导给药与微生物学治愈改善相关(RR 1.14,95%CI 1.03-1.27)。
  • TDM指导给药与治疗失败降低相关(RR 0.79,95%CI 0.66-0.94)。
  • TDM指导给药与目标 attainment 改善相关(RR 1.85,95%CI 1.08-3.16)。
  • 未发现TDM指导给药与死亡率和住院时长存在关联。

局限性

  • 需要更大规模的前瞻性随机试验来更好地评估β-内酰胺类TDM在危重症患者中的效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapeutic drug monitoring (TDM) of beta-lactam antibiotics is recommended to address the variability in exposure observed in critical illness. However, the impact of TDM-guided dosing on clinical outcomes remains unknown. We conducted a systematic review and meta-analysis on TDM-guided dosing and clinical outcomes (all-cause mortality, clinical cure, microbiological cure, treatment failure, hospital and intensive care unit length of stay, target attainment, antibiotic-related adverse events, and emergence of resistance) in critically ill patients with suspected or proven sepsis. Eleven studies (n = 1463 participants) were included. TDM-guided dosing was associated with improved clinical cure (relative risk, 1.17; 95% confidence interval [CI], 1.04 to 1.31), microbiological cure (RR, 1.14; 95% CI, 1.03 to 1.27), treatment failure (RR, 0.79; 95% CI, .66 to .94), and target attainment (RR, 1.85; 95% CI, 1.08 to 3.16). No associations with mortality and length of stay were found. TDM-guided dosing improved clinical and microbiological cure and treatment response. Larger, prospective, randomized trials are required to better assess the utility of beta-lactam TDM in critically ill patients.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Pai Mangalore R, Ashok A, Lee SJ, et al. Beta-Lactam Antibiotic Therapeutic Drug Monitoring in Critically Ill Patients: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2022. PMID: 35731853. doi:10.1093/cid/ciac506

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。